Tekmira partner starts human trials of ALN-TTR01

Alnylam Pharmaceuticals (NASDAQ:ALNY), one of Tekmira Pharmaceuticals‘ (TSX:TKM) partners, has initiated dosing in a Phase 1 clinical trial of its ALN-TTR01 product candidate in patients with transthyretin-mediated amyloidosis (ATTR), a disease that results in damage to the peripheral nerves and heart. ALN-TTR01 is a RNA-interference therapeutic that uses Tekmira’s lipid nanoparticle delivery technology, SNALP (stable [...]

Resverlogix to run parallel Phase 2 studies of lead cardiovascular drug

Resverlogix (TSX:RVX) is planning the next two clinical studies of its lead cardiovascular drug in parallel as a way to accelerate development of RVX-208 and hopefully bring it to market sooner, CEO Donald McCaffrey told shareholders at the annual meeting. They include a Phase 2 pilot intravascular ultrasound (IVUS) trial to examine early lipid effects [...]